Literature DB >> 16601838

Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation.

Ya-Huey Chen1, Hua-Lin Wu, Ching Li, Yi-Hsien Huang, Chi-Wu Chiang, Ming-Ping Wu, Li-Wha Wu.   

Abstract

The molecular mechanism mediated by multiple forms of angiostatin via acting on proliferating vascular endothelium remains elusive. To address whether three forms of angiostatin, K1-3, K1-4 or K1-4.5, utilized similar or distinct pathways to mediate anti-angiogenesis, we adopted an adenoviral expression system to express secretable angiostatin molecules for CM collection. The anti-angiogenic activity of K1-3, K1-4 or K1-4.5 was confirmed by using proliferation, migration, tube formation and apoptotic assays of human endothelial cells. These angiostatin molecules at comparable expression level inhibited various in vitro angiogenesis assays with some variations. Furthermore, K1-3, K1-4 or K1-4.5 increased the expression of p53 protein and its downstream effectors, enhanced FasL-mediated signaling pathways, and decreased activation of AKT. At least three different receptors, Fas, integrin alpha(v)beta3 and ATP synthase, were involved in the anti-angiogenic action of angiostatin molecules. Besides, the expression of 189 genes at mRNA level was significantly altered by K1-3, K1-4 or K1-4.5. More than 70% of these genes participate in growth, inflammation, apoptosis, migration and extracellular matrix. Taken together, K1-3, K1-4 and K1-4.5, regardless of the number of kringles in the angiostatin molecules, mediated anti-angiogenesis via mostly similar pathways. We are the first to demonstrate the involvement of DAPK1 in the mediation of anti-angiogenesis by angiostatin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601838

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  11 in total

1.  Plasma levels of angiostatin and endostatin remain unchanged for the first 3 weeks after colorectal cancer surgery.

Authors:  H M C Shantha Kumara; Samer T Tohme; Xiaohong Yan; Abu Nasar; Anthony J Senagore; Matthew F Kalady; Neil Hyman; Ik Y Kim; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-22       Impact factor: 4.584

Review 2.  Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs.

Authors:  Adriana Albini; Stefano Indraccolo; Douglas M Noonan; Ulrich Pfeffer
Journal:  Clin Exp Metastasis       Date:  2010-04-10       Impact factor: 5.150

3.  Anti-tumoural effects of PlgK1-5 are directly linked to reduced ICAM expression, resulting in hepatoma cell apoptosis.

Authors:  Volker Schmitz; Tilman Sauerbruch; Esther Raskopf
Journal:  Int J Colorectal Dis       Date:  2012-03-28       Impact factor: 2.571

4.  Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation.

Authors:  Neel R Sodha; Richard T Clements; Munir Boodhwani; Shu-Hua Xu; Roger J Laham; Cesario Bianchi; Frank W Sellke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-12-12       Impact factor: 4.733

5.  Tumor angiogenesis: insights and innovations.

Authors:  Fernando Nussenbaum; Ira M Herman
Journal:  J Oncol       Date:  2010-04-26       Impact factor: 4.375

6.  Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin.

Authors:  Tracy Dodd; Luke Wiggins; Rebecca Hutcheson; Erika Smith; Alla Musiyenko; Brenda Hysell; James C Russell; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-18       Impact factor: 8.311

7.  Increased antiangiogenic protein expression in the skeletal muscle of diabetic swine and patients.

Authors:  Neel R Sodha; Munir Boodhwani; Richard T Clements; Shu-Hua Xu; Kamal R Khabbaz; Frank W Sellke
Journal:  Arch Surg       Date:  2008-05

8.  Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism.

Authors:  Wei Mu; David A Long; Xiaosen Ouyang; Anupam Agarwal; Pedro E Cruz; Carlos A Roncal; Takahiko Nakagawa; Xueqing Yu; William W Hauswirth; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-29

9.  Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins.

Authors:  Tong-Young Lee; Stefan Muschal; Elke A Pravda; Judah Folkman; Amir Abdollahi; Kashi Javaherian
Journal:  Blood       Date:  2009-05-22       Impact factor: 22.113

Review 10.  NF-kappa B: a new player in angiostatic therapy.

Authors:  Sebastien P Tabruyn; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2008-02-19       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.